A clinical trial to compare the effects of single injection versus a combination of two injections in pain relief for patients with progressive cervical cancer

PROSPECTIVE RANDOMIZED STUDY TO COMPARE THE EFFICACY OF NEUROLYTIC GANGLION IMPAR BLOCK AND COMBINED SUPERIOR HYPOGASTRIC PLEXUS WITH GANGLION IMPAR BLOCK FOR PAIN RELIEF IN PATIENTS WITH PROGRESSIVE CERVICAL CANCER.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/046992

Enrollment

Registered

2022-11-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: FLUOROSCOPY GUIDED GANGLION IMPAR BLOCK: Group A will receive a fluoroscopy guided Ganglion Impar block. Under strict asepsis, with patient in prone position, under fluoroscopy guidance

Eligibility

Inclusion criteria

Inclusion criteria: 1. All onco-patients with progressive cervical cancers who have recieved first line of treatment with FIGO stage 2.Pain in pelvi-perineal region with pain score >4 3.Patients with progressive cervical cancer receiving chemotherapy who have completed the chemotherapy for atleast 3 weeks before the interventional injection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
50% pain relief after procedure both immediate and delayedTimepoint: Pain score - 1. Before procedure 2.Immediately after procedure 3.2 hours, 12hours, 24hours, 1week, 2 weeks, 1months and 3 months after procedure.	—

Secondary

Measure	Time frame
1. the impact on Morphine consumption (or MEDD) 2. The quality of life(QOL)Timepoint: 1. Pre-procedure 2. 1 week, 1 month, 3 months after the procedure.	—

Countries

India

Contacts

Public ContactDrPoornaMS

Cancer Institute (WIA)

poorna.ms@gmail.com9916053879

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026